Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediPharm LabsFRA:MLZ Receivables Turnover is 1.59 as of Jun. 2026. The stock has 4 warning signs investors should review. Among 947 Drug Manufacturers companies, MediPharm Labs ranks better than 65.68% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. MediPharm Labs's Revenue for the
three
months ended in Jun. 2026 was €6.18 Mil. MediPharm Labs's average Accounts Receivable for the
three
months ended in Jun. 2026 was €3.89 Mil.
Hence, MediPharm Labs's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.59.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
MediPharm Labs Receivables Turnover Related Terms
MediPharm Labs Receivables Turnover Historical Data
* Premium members only.
The historical data trend for MediPharm Labs's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediPharm Labs (FRA:MLZ) has a Receivables Turnover of 1.59 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on MediPharm Labs and its competitors. According to the industry distribution chart, MediPharm Labs ranks #325 out of 947 companies in the Drug Manufacturers industry, placing it in the top 34.3%.
Is MediPharm Labs' Receivables Turnover too high?
MediPharm Labs' current Receivables Turnover is 1.59. The Drug Manufacturers industry median Receivables Turnover is 5.08. MediPharm Labs' value of 1.59 is 68.7% below this industry median. Based on the distribution chart, MediPharm Labs ranks #325 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does MediPharm Labs' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #325 out of 947 companies for Receivables Turnover. This puts MediPharm Labs in the upper half of its industry. The industry median Receivables Turnover is 5.08. MediPharm Labs' value of 1.59 is 68.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediPharm Labs's current Receivables Turnover of 1.59 is 68.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on MediPharm Labs and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediPharm Labs's current Receivables Turnover is 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (FRA:MLZ) is currently considered Fairly Valued. The stock's GF Value™ is €0.04, compared to a current price of €0.04 — trading 3.8% above its estimated fair value. The current Receivables Turnover is 1.59 and 68.7% below the Drug Manufacturers industry median of 5.08. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For MediPharm Labs (FRA:MLZ), the current Receivables Turnover is 1.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MLZ has been successfully added to your 
